BioNTech SE (BNTX) Net Income (2018 - 2025)
BioNTech SE (BNTX) posted Net Income of -$355.0 million for Q4 2025, down 958.16% sequentially from -$33.6 million in Q3 2025, and down 228.03% YoY from $277.3 million in Q4 2024.
BioNTech SE (BNTX) Net Income (2018 - 2025) Analysis & Trends
BioNTech SE has reported Net Income for 8 years, with the latest figure at -$355.0 million in Q4 2025.
- Quarterly Net Income fell 228.03% year-over-year to -$355.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 billion (down 76.14% YoY) and the FY2025 annual result came in at -$1.3 billion, down 80.55% from the prior year.
- Net Income eased to -$355.0 million in Q4 2025 per BNTX's latest filing, from -$33.6 million in the prior quarter.
- Over five years, Net Income peaked at $7.2 billion in Q3 2021 and troughed at -$869.9 million in Q2 2024.
- A 5-year average of $2.0 billion and a median of $385.0 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2021 and 2025: Net Income surged 13561718996.32% in 2021, then tumbled 228.03% in 2025.
- Over 5 years, Net Income stood at $7.2 billion in 2021, then slumped by 42.08% to $4.1 billion in 2022, then sank by 88.13% to $492.7 million in 2023, then sank by 43.72% to $277.3 million in 2024, then plunged by 228.03% to -$355.0 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$355.0 million, -$33.6 million, and -$437.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -355.03 Mn |
| Sep 30, 2025 | -33.55 Mn |
| Jun 30, 2025 | -437.62 Mn |
| Mar 31, 2025 | -437.37 Mn |
| Dec 31, 2024 | 277.30 Mn |
| Sep 30, 2024 | 217.56 Mn |
| Jun 30, 2024 | -869.91 Mn |
| Mar 31, 2024 | -342.31 Mn |
| Dec 31, 2023 | 492.67 Mn |
| Sep 30, 2023 | 174.83 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 7.16 Bn |
| Sep 30, 2021 | 7.22 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 2.60 Bn |